Sign In
A TRIPLET BORTEZOMIB- AND IMMUNOMODULATOR-BASED THERAPY BEFORE AND AFTER DOUBLE ASCT IMPROVES OVERALL SURVIVAL OF NEWLY DIAGNOSED MM PATIENTS: FINAL ANALYSIS OF PHASE 3 GIMEMA-MMY-3006 STUDY
Author(s): ,
Paola Tacchetti
Affiliations:
Bologna University School of Medicine,Seràgnoli Institute of Hematology,Bologna,Italy
,
Francesca Patriarca
Affiliations:
GIMEMA Italian Myeloma Network,Udine,Italy
,
Maria Teresa Petrucci
Affiliations:
GIMEMA Italian Myeloma Network,Roma,Italy
,
Monica Galli
Affiliations:
GIMEMA Italian Myeloma Network,Bergamo,Italy
,
Lucia Pantani
Affiliations:
Bologna University School of Medicine,Seràgnoli Institute of Hematology,Bologna,Italy
,
Luca Dozza
Affiliations:
Bologna University School of Medicine,Seràgnoli Institute of Hematology,Bologna,Italy
,
Francesco Di Raimondo
Affiliations:
GIMEMA Italian Myeloma Network,Catania,Italy
,
Mario Boccadoro
Affiliations:
GIMEMA Italian Myeloma Network,Torino,Italy
,
Massimo Offidani
Affiliations:
GIMEMA Italian Myeloma Network,Ancona,Italy
,
Vittorio Montefusco
Affiliations:
GIMEMA Italian Myeloma Network,Milano,Italy
,
Norbert Pescosta
Affiliations:
GIMEMA Italian Myeloma Network,Bolzano,Italy
,
Antonio Ledda
Affiliations:
GIMEMA Italian Myeloma Network,Cagliari,Italy
,
Tommaso Caravita
Affiliations:
GIMEMA Italian Myeloma Network,Roma,Italy
,
Nicola Cascavilla
Affiliations:
GIMEMA Italian Myeloma Network,Foggia,Italy
,
Barbara Gamberi
Affiliations:
GIMEMA Italian Myeloma Network,Reggio Emilia,Italy
,
Piero Maria Stefani
Affiliations:
GIMEMA Italian Myeloma Network,Treviso,Italy
,
Carolina Terragna
Affiliations:
Bologna University School of Medicine,Seràgnoli Institute of Hematology,Bologna,Italy
,
Giulia Marzocchi
Affiliations:
Bologna University School of Medicine,Seràgnoli Institute of Hematology,Bologna,Italy
,
Felicetto Ferrara
Affiliations:
GIMEMA Italian Myeloma Network,Napoli,Italy
,
Valerio De Stefano
Affiliations:
GIMEMA Italian Myeloma Network,Roma,Italy
,
Elena Zamagni
Affiliations:
Bologna University School of Medicine,Seràgnoli Institute of Hematology,Bologna,Italy
Michele Cavo
Affiliations:
Bologna University School of Medicine,Seràgnoli Institute of Hematology,Bologna,Italy
EHA Library. Tacchetti P.
Jun 15, 2018; 214500
Paola Tacchetti
Paola Tacchetti
Contributions
×
Abstract

Abstract: S105

Type: Oral Presentation

Presentation during EHA23: On Friday, June 15, 2018 from 11:30 - 11:45

Location: Victoria Hall

Background
The phase 3 GIMEMA-MMY-3006 study comparing bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem-cell transplantation (ASCT) for newly diagnosed multiple myeloma (MM) provided demonstration of prolonged PFS, but not OS, for patients randomized to the VTD arm (Cavo M et al, Lancet 2010; Blood 2012).  Based  on superior rates of high quality response  and PFS,  a bortezomib-based triplet is currently considered as the standard induction therapy for ASCT-eligible MM patients. However, no data from prospective  phase  3  trials have so far shown an OS benefit from incorporation of bortezomib and an immunomodulatory into ASCT.

Aims
The current analysis was aimed at evaluating long term results of the GIMEMA-MMY-3006 study.

Methods
Overall, 474 patients were included in the trial, and of these 236 were randomized to VTD and 238 to the TD arm. Median follow-up for surviving patients was 92.8 months (IQR: 59.6-123.0). Analyses were performed on an intention-to-treat basis.

Results
Median PFS was 56.5 months for patients randomly assigned to the VTD arm, and 41.3 months for those in the TD group (HR=0.66, p<0.001). PFS benefit with VTD was seen for patients with ISS stage II-III (HR=0.68, p=0.007) and ISS stage I (HR=0.60, p=0.005), as well as for those with t(4;14) and/or del(17p) positivity (HR=0.45, p<0.001) and negativity (HR=0.66, p=0.003). Median OS was not yet reached in the VTD arm and was 118.6 months in the TD arm (HR=0.71, p=0.024), representing a 29% reduction in the risk of death with incorporation of VTD into double ASCT (Figure 1). Estimated rates of OS at 93 months were 67.6% and 58.5%, respectively. Superior OS benefit with VTD over TD was retained across prespecified subgroups of patients with both high-risk and low-risk disease, including those with ISS stages III (HR=0.52, p=0.056), ISS stage I (HR=0.56, p=0.033) and cytogenetics by FISH. In particular, VTD significantly prolonged the OS of patients with both t(4;14) and/or del(17p) positivity (HR=0.57, p=0.031) and negativity (HR=0.66, p=0.034). On multivariate Cox regression analysis, randomization to VTD was an independent factor predicting for prolonged PFS (HR=0.62, p<0.001) and OS (HR=0.61,  p=0.001). Additional disease-related variables with a favorable impact on PFS and OS were absence of t(4;14) and/or del(17p) (HR=0.50, p<0.001; HR=0.49, p<0.001), and β2-microglobulin <3.5 mg/L (HR=0.60, p<0.001; HR=0.51, p<0.001). Further analyses of PFS2, time to second anti-MM therapy, and second primary malignancies will be presented at the meeting.

Conclusion
With an extended median follow-up of 7.6 years,  a persistent PFS benefit with incorporation of VTD into ASCT was confirmed. Moreover, a longer OS from primary randomization to VTD versus TD was demonstrated in the overall population, as well as in subgroups of patients with high risk and low risk MM.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Autologous hematopoietic stem cell transplantation, bortezomib, Myeloma

Premium Sponsors
Major Sponsors

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies